A new restructuring program in the Innovative Medicine segment aims to optimize operations by exiting sites and suppliers by 2029, with $200M in costs already recorded in Q2 2026. This, along with ongoing restructuring in MedTech, signals major operational shifts and a need for solutions in supply chain logistics, asset management, and project management.
Filing excerpt
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10qdivestitureGet every 10-Q signal for Johnson & Johnson and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/13ccdcaf-c47e-40a2-ad9d-5a1d432d197f returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.
{
"signal_id": "13ccdcaf-c47e-40a2-ad9d-5a1d432d197f",
"signal_type": "sec-10q",
"signal_subtype": "divestiture",
"detected_at": "2026-07-28T07:07:20.015+00:00",
"company": {
"name": "Johnson & Johnson",
"domain": "jnj.com"
},
"data": {
"detail": "A new restructuring program in the Innovative Medicine segment aims to optimize operations by exiting sites and suppliers by 2029, with $200M in costs already recorded in Q2 2026. This, along with ongoing restructuring in MedTech, signals major operational shifts and a need for solutions in supply chain logistics, asset management, and project management.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Upper estimate for supply chain restructuring program costs through 2029",
"dollar_millions": 750
},
"summary": "J&J initiates $650M-$750M supply chain restructuring, exiting manufacturing locations.",
"excerpts": "In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations.",
"relevance": 0.8,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm",
"filing_date": "2026-07-23",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/28",
"sales_relevance": "Carve-out support needed",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/13ccdcaf-c47e-40a2-ad9d-5a1d432d197f \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.